Reaction
B Precursor Type Acute Leukaemia reporting signals
As of the last recalculation, B Precursor Type Acute Leukaemia appears in 384 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is BLINATUMOMAB (PRR 1,550.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Blinatumomab | 168 | 1,550.8 | 1,576.3 |
| Melphalan | 24 | 60.9 | 61.0 |
| Melphalan Hydrochloride | 25 | 57.7 | 57.8 |
| Bleomycin Sulfate | 9 | 48.3 | 48.4 |
| Cytarabine | 31 | 30.3 | 30.3 |
| Bortezomib | 44 | 30.0 | 30.0 |
| Thiotepa | 5 | 28.7 | 28.8 |
| Pegaspargase | 5 | 22.4 | 22.4 |
| Carfilzomib | 9 | 17.6 | 17.6 |
| Lenalidomide | 80 | 12.7 | 12.7 |